INTRODUCTION {#s1}
============

Cervical cancer is one of the most common malignancies in women worldwide, with an estimated global incidence of 470,000 new cases and approximately 233,000 deaths per year \[[@R1]\]. Compared to developed countries, the incidence and mortality of cervical cancer is higher in low-resource countries \[[@R2]\]. High-risk human papillomavirus (HPV) infections are the main aetiological factors of cervical intraepithelial neoplasia (CIN) in women, and persisting high-risk HPV infections significantly facilitate the development of CIN to cervical cancer. However, evidence suggests that host genetic factors are also involved in the initiation and development of cervical cancer \[[@R3]--[@R5]\].

MicroRNAs (miRNAs) are a group of short RNAs with 20-23 noncoding nucleotides. MiRNAs play important roles in various biological processes through binding to the 3′-untranslate region (UTR) of target mRNAs and inhibiting protein translation or degrading mRNAs. MiRNAs regulate more than 60% of all human genes \[[@R6]\] and are involved in crucial physiological processes, such as proliferation, apoptosis, differentiation, tumourigenesis and cancer metastasis \[[@R7]--[@R10]\].

Recent studies have demonstrated the aberrant expression of miRNAs in cervical cancer and their contribution to tumour generation \[[@R11]\]. Functional studies have shown that miRNAs impact tumour cell fate through the regulation of various cell signalling pathways \[[@R12]\]. Thus, miRNAs act as oncogenic or anti-oncogenic molecules in the initiation and development of cervical cancer \[[@R13]\]. For example, miR-218 functions as a tumour suppressor through targeting focal adhesion pathways and the SLIT2-ROBO1 pathway, and inhibiting cancer cell migration and invasion. Single nucleotide polymorphisms (SNPs) in miRNA genes have been associated with various human diseases \[[@R14]--[@R16]\]. In 2016, Wang *et al*. reported that rs767649 in miR-155 is associated with cervical cancer \[[@R17]\].

In the present study, we searched for SNPs in nineteen miRNAs associated with cervical cancer \[[@R18]\]. Subsequently, we conducted an association study in patients with CIN, patients with cervical cancer and healthy individuals to investigate the relationship of the SNPs in miRNAs with CIN and cervical cancer in a Chinese Han population.

RESULTS {#s2}
=======

Subject characteristics {#s2_1}
-----------------------

Table [1](#T1){ref-type="table"} lists the characteristics of subjects in the present study. There was no significant difference in age between CIN, cervical cancer and control groups (*p*\>0.05). In the cervical cancer group, there were 91 individuals with adenocarcinoma (AC), 501 individuals with squamous cell carcinoma (SCC) and 17 individuals with other pathological types.

###### The characteristics of the subjects in the present subjects

                         Cervical cancer   CIN          Control      *P* value
  ---------------------- ----------------- ------------ ------------ -----------
  N                      609               400          583          
  Ages                   44.22±9.08        43.46±9.25   43.89±5.93   0.345
  **Pathologic types**                                               
  SCC                    501                                         
  AC                     91                                          
  Others                 17                                          

The sequencing results of nineteen miRNA genes {#s2_2}
----------------------------------------------

Five of the nineteen miRNAs showed polymorphisms in 50 healthy individuals. The polymorphisms are rs11134527 in pri-miR-218-2, rs74693964 in pri-miR-145, rs6062251 in pri-miR-133a2, rs531564 in pri-miR-124-1 and rs1834306 in pri-miR-100.

Association of the five SNPs with cervical cancer {#s2_3}
-------------------------------------------------

The allelic and genotypic frequencies for the five SNPs in miRNAs are displayed in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively. All five SNPs were in Hardy-Weinberg equilibrium (HWE) in the control group (*P*\>0.05). The A allelic frequency of rs11134527 in CIN (59.3%) and cervical cancer (60.8%) groups was significantly different from that in the control group(64.9%) (*P*=0.011 and 0.035, respectively), and the A allele occurred more frequently in the control group compared with the CIN (OR=0.786; 95%CI: 0.653-0.946) and cervical cancer groups (OR=0.836; 95%CI: 0.708-0.988). The C allelic frequency of rs531564 in the cervical cancer group (14.6%) was significantly different from that in the control (11.3%) and CIN groups (11.0%) (*P*=0.017 and 0.019, respectively), and the C allele occurred more frequently in the cervical cancer group compared to the control groups (OR=1.341;95%CI:1.054-1.706) and CIN (OR=1.385;95%CI:1.054-1.819). The genotypic frequencies of rs11134527 (A/A, 36.7%; A/G, 45.0%; and G/G, 18.2%) and rs6062251 (C/C, 8.5%; C/T, 51.7%; and T/T, 39.8%) in the CIN group were significantly different from those in the control (A/A, 41.5%; A/G, 46.8%; and G/G, 11.7%) (*P*=0.013) and cervical cancer groups (C/C, 12.8%; C/T, 42.5%; and T/T, 44.7%) (*P*=0.007), respectively. Moreover, the genotypic frequencies of rs531564 in the cervical cancer group (C/C,2.8%; C/G,23.6%; and G/G,73.6%) were significantly different from that in the CIN (C/C,1.0%; C/G,20.0%; and G/G,79.0%) and control groups (C/C,1.2%; C/G,20.2%; and G/G,78.6%) (*P*=0.047 and 0.043, respectively). The allelic and genotypic frequencies of rs74693964 and rs1834306 were not significantly different among the three groups.

###### Allelic frequencies comparison of the five SNPs among control, CIN and cervical cancer groups

  SNPs              Alleles(*n*, %)   Control VS CIN   CIN VS cervical cancer   Control VS cervical cancer                                                      
  ----------------- ----------------- ---------------- ------------------------ ---------------------------- ----------- -------------------------- ----------- --------------------------
  rs11134527        A                 G                **0.011**                **0.786\[0.653-0.946\]**     0.499       1.065\[0.888-1.277\]       **0.035**   **0.836\[0.708-0.988\]**
  Control           757(64.9%)        409(35.1%)                                                                                                                
  CIN               474(59.3%)        326(40.7%)                                                                                                                
  Cervical cancer   740(60.8%)        478(39.2%)                                                                                                                
  rs74693964        C                 T                0.502                    1.187\[0.719-1.960\]         0.585       1.158\[0.684-1.963\]       0.174       1.375\[0.867-2.180\]
  Control           1123(96.3%)       43(3.7%)                                                                                                                  
  CIN               775(96.9%)        25(3.1%)                                                                                                                  
  Cervical cancer   1185(97.3%)       33(2.7%)                                                                                                                  
  rs6062251         C                 T                0.912                    1.011\[0.836-1.222\]         0.888       0.987\[0.818-1.191\]       0.975       0.997\[0.842-1.181\]
  Control           398(34.1%)        768(65.9%)                                                                                                                
  CIN               275(34.4%)        525(65.6%)                                                                                                                
  Cervical cancer   415(34.1%)        803(65.9%)                                                                                                                
  rs531564          C                 G                0.825                    0.968\[0.727-1.289\]         **0.019**   **1.385\[1.054-1.819\]**   **0.017**   **1.341\[1.054-1.706\]**
  Control           132(11.3%)        1034(88.7%)                                                                                                               
  CIN               88(11.0%)         712(89.0%)                                                                                                                
  Cervical cancer   178(14.6%)        1040(85.4%)                                                                                                               
  rs1834306         A                 G                0.964                    1.004\[0.838-1.203\]         0.701       1.036\[0.866-1.238\]       0.634       1.040\[0.885-1.221\]
  Control           541(46.4%)        625(53.6%)                                                                                                                
  CIN               372(46.5%)        428(53.5%)                                                                                                                
  Cervical cancer   577(47.4%)        641(52.6%)                                                                                                                

###### Genotypic frequencies comparison of the five SNPs among control, CIN and cervical cancer groups

  SNPs              Genotypes(*n*, %)   *P* value                                         
  ----------------- ------------------- ------------ ------------ ----------- ----------- -----------
  rs11134527        A/A                 A/G          G/G          **0.013**   0.366       0.101
  Control           242(41.5%)          273(46.8%)   68(11.7%)                            
  CIN               147(36.7%)          180(45.0%)   73(18.2%)                            
  Cervical cancer   233(36.6%)          294(48.3%)   92(15.1%)                            
  rs74693964        C/C                 C/T          T/T          0.702       0.454       0.302
  Control           541(92.8%)          41(7.0%)     1(0.2%)                              
  CIN               376(94.0%)          23(5.8%)     1(0.3%)                              
  Cervical cancer   576(94.6%)          33(5.4%)     0(0.0%)                              
  rs6062251         C/C                 C/T          T/T          0.225       **0.007**   0.293
  Control           63(10.8%)           272(46.7%)   248(42.5%)                           
  CIN               34(8.5%)            207(51.7%)   159(39.8%)                           
  Cervical cancer   78(12.8%)           259(42.5%)   272(44.7%)                           
  rs531564          C/C                 C/G          G/G          **0.952**   **0.047**   **0.043**
  Control           7(1.2%)             118(20.2%)   458(78.6%)                           
  CIN               4(1.0%)             80(20.0%)    316(79.0%)                           
  Cervical cancer   17(2.8%)            144(23.6%)   448(73.6%)                           
  rs1834306         A/A                 A/G          G/G          0.811       0.834       0.875
  Control           126(21.6%)          289(49.6%)   168(28.8%)                           
  CIN               91(22.8%)           190(47.5%)   119(29.7%)                           
  Cervical cancer   139(22.8%)          299(49.1%)   171(28.1%)                           

Model of inheritance analysis {#s2_4}
-----------------------------

Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"} present the results of the analyses of different models of inheritance for the five SNPs. The Akaike information criterion (AIC) and Bayesian information criterion (BIC) were calculated to identify the best inheritance model for each SNP. The model with smallest AIC and BIC values was the best-fit inheritance model. The genotypic frequency of rs11134527 A/A-A/G was significantly different from G/G (*P*=0.018) under the recessive model between control and CIN groups. In this model, the A/A-A/G genotype was associated with a decreased risk of CIN (OR=0.61; 95%CI: 0.41-0.92). A comparison between CIN and cervical cancer groups revealed that the genotypic frequencies of rs6062251 were significantly different in the overdominant model (*P*=0.007). In the overdominant model, the T/T-C/C genotype of rs6062251 was associated with increased risk of cervical cancer (OR=1.45; 95%CI:1.11-1.90). A comparison of control and cervical cancer groups revealed that the genotypic frequencies of rs531564 were significantly different in the log-additive model (*P*=0.022). In this model, the genotype 2G/G-C/G of rs531564 (OR=0.75; 95%CI: 0.58-0.96) was associated with a decreased risk of cervical cancer.

###### Different inheritance models analysis of the SNPs in miRNA genes in the comparison between control and CIN groups

  SNPs           Model         Genotypes     CIN (*n*, %)           Control (*n*, %)   After adjusted by Age                
  -------------- ------------- ------------- ---------------------- ------------------ ----------------------- ------------ ------------
  rs11134527                                                                                                                
  Codominant     A/A           147 (36.8%)   242 (41.5%)            1                  0.062                   1215.4       1450.2
  A/G            180 (45.0%)   273 (46.8%)   0.99 (0.72-1.35)                                                               
  G/G            73 (18.2%)    68 (11.7%)    0.61 (0.39-0.94)                                                               
  Dominant       A/A           147 (36.8%)   242 (41.5%)            1                  0.390                   1218.3       1448.1
  A/G-G/G        253 (63.2%)   341 (58.5%)   0.88 (0.66-1.18)                                                               
  Recessive      A/A-A/G       327 (81.8%)   515 (88.3%)            **1**              **0.018**               **1213.4**   **1443.3**
  G/G            73 (18.2%)    68 (11.7%)    **0.61 (0.41-0.92)**                                                           
  Overdominant   A/A-G/G       220 (55.0%)   310 (53.2%)            1                  0.420                   1218.3       1448.2
  A/G            180 (45.0%)   273 (46.8%)   1.13 (0.85-1.50)                                                               
  Log-additive   \-\--         \-\--         \-\--                  0.82 (0.67-1.02)   0.069                   1215.7       1445.5
  rs74693964                                                                                                                
  Codominant     C/C           376 (94%)     541 (92.8%)            1                  0.590                   1220.0       1454.7
  C/T            23 (5.8%)     41 (7.0%)     1.37 (0.74-2.54)                                                               
  T/T            1 (0.2%)      1 (0.2%)      1.34 (0.05-32.99)                                                              
  Dominant       C/C           376 (94.0%)   541 (92.8%)            1                  0.310                   1218.0       1447.8
  C/T-T/T        24 (6.0%)     42 (7.2%)     1.37 (0.74-2.52)                                                               
  Recessive      C/C-C/T       399 (99.8%)   582 (99.8%)            1                  0.870                   1219.0       1448.8
  T/T            1 (0.2%)      1 (0.2%)      1.32 (0.05-32.33)                                                              
  Overdominant   C/C-T/T       377 (94.2%)   542 (93.0%)            1                  0.310                   1218.0       1447.8
  C/T            23 (5.8%)     41 (7.0%)     1.37 (0.74-2.54)                                                               
  Log-additive   \-\--         \-\--         \-\--                  1.34 (0.75-2.39)   0.310                   1218.0       1447.9
  rs6062251                                                                                                                 
  Codominant     T/T           159 (39.8%)   248 (42.5%)            1                  0.200                   1217.7       1452.5
  C/T            207 (51.8%)   272 (46.7%)   0.78 (0.58-1.06)                                                               
  C/C            34 (8.5%)     63 (10.8%)    1.07 (0.64-1.80)                                                               
  Dominant       T/T           159 (39.8%)   248 (42.5%)            1                  0.180                   1217.2       1447.1
  C/T-C/C        241 (60.2%)   335 (57.5%)   0.82 (0.61-1.10)                                                               
  Recessive      T/T-C/T       366 (91.5%)   520 (89.2%)            1                  0.410                   1218.3       1448.2
  C/C            34 (8.5%)     63 (10.8%)    1.23 (0.75-2.00)                                                               
  Overdominant   T/T-C/C       193 (48.2%)   311 (53.3%)            1                  0.074                   1215.8       1445.7
  C/T            207 (51.8%)   272 (46.7%)   0.77 (0.58-1.03)                                                               
  Log-additive   \-\--         \-\--         \-\--                  0.93 (0.74-1.16)   0.520                   1218.6       1448.5
  rs531564                                                                                                                  
  Codominant     G/G           316 (79.0%)   458 (78.6%)            1                  0.860                   1220.7       1455.5
  C/G            80 (20.0%)    118 (20.2%)   0.96 (0.67-1.36)                                                               
  C/C            4 (1.0%)      7 (1.2%)      1.39 (0.35-5.57)                                                               
  Dominant       G/G           316 (79.0%)   458 (78.6%)            1                  0.880                   1219.0       1448.8
  C/G-C/C        84 (21.0%)    125 (21.4%)   0.97 (0.69-1.38)                                                               
  Recessive      G/G-C/G       396 (99.0%)   576 (98.8%)            1                  0.630                   1218.8       1448.6
  C/C            4 (1.0%)      7 (1.2%)      1.40 (0.35-5.62)                                                               
  Overdominant   G/G-C/C       320 (80.0%)   465 (79.8%)            1                  0.780                   1218.9       1448.8
  C/G            80 (20.0%)    118 (20.2%)   0.95 (0.67-1.36)                                                               
  Log-additive   \-\--         \-\--         \-\--                  1.00 (0.72-1.38)   0.980                   1219.0       1448.9
  rs1834306                                                                                                                 
  Codominant     G/G           119 (29.8%)   168 (28.8%)            1                  0.750                   1220.4       1455.2
  A/G            190 (47.5%)   289 (49.6%)   1.13 (0.81-1.58)                                                               
  A/A            91 (22.8%)    126 (21.6%)   1.05 (0.70-1.56)                                                               
  Dominant       G/G           119 (29.8%)   168 (28.8%)            1                  0.530                   1218.6       1448.5
  A/G-A/A        281 (70.2%)   415 (71.2%)   1.10 (0.81-1.51)                                                               
  Recessive      G/G-A/G       309 (77.2%)   457 (78.4%)            1                  0.860                   1219.0       1448.8
  A/A            91 (22.8%)    126 (21.6%)   0.97 (0.69-1.37)                                                               
  Overdominant   G/G-A/A       210 (52.5%)   294 (50.4%)            1                  0.470                   1218.5       1448.3
  A/G            190 (47.5%)   289 (49.6%)   1.11 (0.84-1.48)                                                               
  Log-additive   \-\--         \-\--         \-\--                  1.03 (0.84-1.26)   0.770                   1218.9       1448.8

###### Different inheritance models analysis of the SNPs in miRNA genes in the comparison between CIN and cervical cancer groups

  SNPs           Models        Genotypes      Cervical cancer (*n*, %)   CIN (*n*, %)       After adjusted by Age                
  -------------- ------------- -------------- -------------------------- ------------------ ----------------------- ------------ ------------
  rs11134527                                                                                                                     
  Codominant     A/A           223 (36.6%)    147 (36.8%)                1                  0.290                   1365.1       1615.8
  A/G            294 (48.3%)   180 (45.0%)    0.89 (0.66-1.19)                                                                   
  G/G            92 (15.1%)    73 (18.2%)     1.20 (0.81-1.78)                                                                   
  Dominant       A/A           223 (36.6%)    147 (36.8%)                1                  0.770                   1365.5       1611.3
  A/G-G/G        386 (63.4%)   253 (63.2%)    0.96 (0.73-1.27)                                                                   
  Recessive      A/A-A/G       517 (84.9%)    327 (81.8%)                1                  0.170                   1363.7       1609.5
  G/G            92 (15.1%)    73 (18.2%)     1.28 (0.90-1.84)                                                                   
  Overdominant   A/A-G/G       315 (51.7%)    220 (55.0%)                1                  0.200                   1363.9       1609.7
  A/G            294 (48.3%)   180 (45.0%)    0.84 (0.64-1.10)                                                                   
  Log-additive   \-\--         \-\--          \-\--                      1.05 (0.87-1.27)   0.600                   1365.3       1611.1
  rs74693964                                                                                                                     
  Codominant     C/C           576 (94.6%)    376 (94.0%)                1                  0.510                   1366.2       1617
  C/T            33 (5.4%)     23 (5.8%)      0.96 (0.54-1.73)                                                                   
  T/T            0 (0.0%)      1 (0.2%)       NA (0.00-NA)                                                                       
  Dominant       C/C           576 (94.6%)    376 (94.0%)                1                  1                       1365.5       1611.4
  C/T-T/T        33 (5.4%)     24 (6.0%)      1.00 (0.56-1.78)                                                                   
  Recessive      C/C-C/T       609 (100.0%)   399 (99.8%)                1                  0.250                   1364.2       1610.1
  T/T            0 (0.0%)      1 (0.2%)       NA (0.00-NA)                                                                       
  Overdominant   C/C-T/T       576 (94.6%)    377 (94.2%)                1                  0.890                   1365.5       1611.4
  C/T            33 (5.4%)     23 (5.8%)      0.96 (0.54-1.72)                                                                   
  Log-additive   \-\--         \-\--          \-\--                      1.04 (0.60-1.82)   0.890                   1365.5       1611.4
  rs6062251                                                                                                                      
  Codominant     T/T           272 (44.7%)    159 (39.8%)                1                  0.017                   1359.4       1610.2
  C/T            259 (42.5%)   207 (51.8%)    1.39 (1.05-1.85)                                                                   
  C/C            78 (12.8%)    34 (8.5%)      0.81 (0.50-1.31)                                                                   
  Dominant       T/T           272 (44.7%)    159 (39.8%)                1                  0.088                   1362.6       1608.5
  C/T-C/C        337 (55.3%)   241 (60.2%)    1.27 (0.96-1.67)                                                                   
  Recessive      T/T-C/T       531 (87.2%)    366 (91.5%)                1                  0.089                   1362.7       1608.5
  C/C            78 (12.8%)    34 (8.5%)      0.68 (0.43-1.07)                                                                   
  Overdominant   T/T-C/C       350 (57.5%)    193 (48.2%)                **1**              **0.007**               **1358.1**   **1604.0**
  C/T            259 (42.5%)   207 (51.8%)    **1.45 (1.11-1.90)**                                                               
  Log-additive   \-\--         \-\--          \-\--                      1.05 (0.86-1.29)   0.620                   1365.3       1611.1
  rs531564                                                                                                                       
  Codominant     G/G           448 (73.6%)    316 (79.0%)                1                  0.072                   1362.3       1613.0
  C/G            144 (23.6%)   80 (20.0%)     0.85 (0.61-1.18)                                                                   
  C/C            17 (2.8%)     4 (1.0%)       0.32 (0.11-1.00)                                                                   
  Dominant       G/G           448 (73.6%)    316 (79.0%)                1                  0.140                   1363.3       1609.2
  C/G-C/C        161 (26.4%)   84 (21.0%)     0.79 (0.58-1.08)                                                                   
  Recessive      G/G-C/G       592 (97.2%)    396 (99.0%)                1                  0.038                   1361.2       1607.1
  C/C            17 (2.8%)     4 (1.0%)       0.34 (0.11-1.03)                                                                   
  Overdominant   G/G-C/C       465 (76.3%)    320 (80.0%)                1                  0.400                   1364.8       1610.7
  C/G            144 (23.6%)   80 (20.0%)     0.87 (0.63-1.20)                                                                   
  Log-additive   \-\--         \-\--          \-\--                      0.76 (0.58-1.01)   0.057                   1361.9       1607.8
  rs1834306                                                                                                                      
  Codominant     G/G           171 (28.1%)    119 (29.8%)                1                  0.84                    1367.2       1617.9
  A/G            299 (49.1%)   190 (47.5%)    0.92 (0.67-1.26)                                                                   
  A/A            139 (22.8%)   91 (22.8%)     0.90 (0.62-1.32)                                                                   
  Dominant       G/G           171 (28.1%)    119 (29.8%)                1                  0.56                    1365.2       1611
  A/G-A/A        438 (71.9%)   281 (70.2%)    0.92 (0.68-1.23)                                                                   
  Recessive      G/G-A/G       470 (77.2%)    309 (77.2%)                1                  0.75                    1365.4       1611.3
  A/A            139 (22.8%)   91 (22.8%)     0.95 (0.69-1.31)                                                                   
  Overdominant   G/G-A/A       310 (50.9%)    210 (52.5%)                1                  0.79                    1365.5       1611.3
  A/G            299 (49.1%)   190 (47.5%)    0.96 (0.74-1.26)                                                                   
  Log-additive   \-\--         \-\--          \-\--                      0.95 (0.78-1.14)   0.58                    1365.2       1611.1

###### Different inheritance models analysis of the SNPs in miRNA genes in the comparison between control and cervical cancer groups

  SNPs           Model         Genotypes      Cervical cancer (*n*, %)   Control (*n*, %)       After adjusted by Age                
  -------------- ------------- -------------- -------------------------- ---------------------- ----------------------- ------------ ------------
  rs11134527                                                                                                                         
  Codominant     A/A           223 (36.6%)    242 (41.5%)                1                      0.190                   1577.2       1826.3
  A/G            294 (48.3%)   273 (46.8%)    0.83 (0.64-1.08)                                                                       
  G/G            92 (15.1%)    68 (11.7%)     0.72 (0.49-1.07)                                                                       
  Dominant       A/A           223 (36.6%)    242 (41.5%)                1                      0.095                   1575.7       1819.7
  A/G-G/G        386 (63.4%)   341 (58.5%)    0.81 (0.63-1.04)                                                                       
  Recessive      A/A-A/G       517 (84.9%)    515 (88.3%)                1                      0.230                   1577.1       1821.1
  G/G            92 (15.1%)    68 (11.7%)     0.80 (0.56-1.15)                                                                       
  Overdominant   A/A-G/G       315 (51.7%)    310 (53.2%)                1                      0.420                   1577.9       1821.9
  A/G            294 (48.3%)   273 (46.8%)    0.90 (0.71-1.15)                                                                       
  Log-additive   \-\--         \-\--          \-\--                      0.85 (0.70-1.01)       0.070                   1575.2       1819.2
  rs74693964                                                                                                                         
  Codominant     C/C           576 (94.6%)    541 (92.8%)                1                      0.440                   1578.9       1828.0
  C/T            33 (5.4%)     41 (7.0%)      1.23 (0.75-2.04)                                                                       
  T/T            0 (0.0%)      1 (0.2%)       NA (0.00-NA)                                                                           
  Dominant       C/C           576 (94.6%)    541 (92.8%)                1                      0.370                   1577.7       1821.7
  C/T-T/T        33 (5.4%)     42 (7.2%)      1.26 (0.76-2.07)                                                                       
  Recessive      C/C-C/T       609 (100.0%)   582 (99.8%)                1                      0.320                   1577.6       1821.6
  T/T            0 (0.0%)      1 (0.2%)       NA (0.00-NA)                                                                           
  Overdominant   C/C-T/T       576 (94.6%)    542 (93%)                  1                      0.420                   1577.9       1821.9
  C/T            33 (5.4%)     41 (7.0%)      1.23 (0.74-2.03)                                                                       
  Log-additive   \-\--         \-\--          \-\--                      1.28 (0.78-2.09)       0.330                   1577.6       1821.6
  rs6062251                                                                                                                          
  Codominant     T/T           272 (44.7%)    248 (42.5%)                1                      0.480                   1579.1       1828.2
  C/T            259 (42.5%)   272 (46.7%)    1.12 (0.86-1.45)                                                                       
  C/C            78 (12.8%)    63 (10.8%)     0.90 (0.60-1.34)                                                                       
  Dominant       T/T           272 (44.7%)    248 (42.5%)                1                      0.600                   1578.2       1822.2
  C/T-C/C        337 (55.3%)   335 (57.5%)    1.07 (0.83-1.37)                                                                       
  Recessive      T/T-C/T       531 (87.2%)    520 (89.2%)                1                      0.390                   1577.8       1821.8
  C/C            78 (12.8%)    63 (10.8%)     0.85 (0.58-1.24)                                                                       
  Overdominant   T/T-C/C       350 (57.5%)    311 (53.3%)                1                      0.280                   1577.4       1821.4
  C/T            259 (42.5%)   272 (46.7%)    1.14 (0.90-1.46)                                                                       
  Log-additive   \-\--         \-\--          \-\--                      1.00 (0.83-1.20)       0.980                   1578.5       1822.5
  rs531564                                                                                                                           
  Codominant     G/G           448 (73.6%)    458 (78.6%)                1                      0.038                   1574.0       1823.1
  C/G            144 (23.6%)   118 (20.2%)    0.81 (0.61-1.10)                                                                       
  C/C            17 (2.8%)     7 (1.2%)       0.36 (0.15-0.91)                                                                       
  Dominant       G/G           448 (73.6%)    458 (78.6%)                1                      0.060                   1575.0       1819
  C/G-C/C        161 (26.4%)   125 (21.4%)    0.76 (0.57-1.01)                                                                       
  Recessive      G/G-C/G       592 (97.2%)    576 (98.8%)                1                      0.031                   1573.9       1817.9
  C/C            17 (2.8%)     7 (1.2%)       0.38 (0.15-0.95)                                                                       
  Overdominant   G/G-C/C       465 (76.3%)    465 (79.8%)                1                      0.23                    1577.1       1821.1
  C/G            144 (23.6%)   118 (20.2%)    0.84 (0.62-1.12)                                                                       
  Log-additive   **\-\--**     **\-\--**      **\-\--**                  **0.75 (0.58-0.96)**   **0.022**               **1573.3**   **1817.3**
  rs1834306                                                                                                                          
  Codominant     G/G           171 (28.1%)    168 (28.8%)                1                      1                       1580.5       1829.6
  A/G            299 (49.1%)   289 (49.6%)    0.99 (0.74-1.32)                                                                       
  A/A            139 (22.8%)   126 (21.6%)    0.99 (0.70-1.41)                                                                       
  Dominant       G/G           171 (28.1%)    168 (28.8%)                1                      0.93                    1578.5       1822.5
  A/G-A/A        438 (71.9%)   415 (71.2%)    0.99 (0.75-1.30)                                                                       
  Recessive      G/G-A/G       470 (77.2%)    457 (78.4%)                1                      0.99                    1578.5       1822.5
  A/A            139 (22.8%)   126 (21.6%)    1.00 (0.74-1.35)                                                                       
  Overdominant   G/G-A/A       310 (50.9%)    294 (50.4%)                1                      0.93                    1578.5       1822.5
  A/G            299 (49.1%)   289 (49.6%)    0.99 (0.77-1.26)                                                                       
  Log-additive   \-\--         \-\--          \-\--                      1.00 (0.84-1.19)       0.96                    1578.5       1822.5

DISCUSSION {#s3}
==========

Evidence has shown that miRNAs are involved in the initiation and development of various types of cancers, and these molecules function as anti-oncogenes or oncogenes. SNPs in miRNAs, including primary, precursor and mature miRNA, may change the expression level and alter the binding affinity of miRNAs, and further regulate the expression of the target genes, thereby markedly impacting cell pathway regulation, which defines cellular fates \[[@R19], [@R20]\]. In the present study, we observed that rs11134527 in pri-miR-218-2 and rs531564 in pri-miR-124-1 were associated with CIN and cervical cancer in a Chinese Han population.

In 2013, Yamamoto N *et al*. reported that the expression of miR-218 was significantly lower in cervical cancer tissues than in adjacent non-cancerous tissues, and the restoration of miR-218 significantly inhibited cancer cell proliferation, migration and invasion \[[@R21]\]. In addition, the anti-oncogene function of miR-218 has been reported in several types of cancers through targeting several oncogenes, such as Rictor (oral cancer), EGFR (non-small cell lung cancer), ROBO1 receptor (gastric cancer) and LAMB3 (cervical cancer) \[[@R22]--[@R25]\]. Several studies have investigated the association of rs11134527 with different diseases (Table [7](#T7){ref-type="table"}) \[[@R26]--[@R28]\]; however, these studies provided contradictory results. In the present study, rs11134527 in pri-miR-218-2 was associated with CIN and cervical cancer in a Chinese Han population, and the A allele of rs11134527 was associated with a lower risk of CIN (*P*=0.011; OR=0.786; 95%CI:0.653-0.946) and cervical cancer (*P*=0.035; OR=0.836; 95%CI:0.708-0.988) in a comparison of CIN and cervical cancer groups with control group. The genotype A/A-A/G showed a lower risk of cervical cancer compared with the G/G genotype using the recessive model in a comparison of the CIN group with the control group (*P*=0.018; OR=0.61;95%CI:0.41-0.92). However, this result was inconsistent with Shi *et al*. \[[@R28]\] whose study showed that the G/G genotype was associated with a decreased risk of cervical cancer compared with AA and A/G genotypes. The discrepancy between these results might reflect different sample sizes and populations in the two studies, and unfortunately, the Shi *et al*. study did not focus on the association with CIN, thus, we could not compare the results between CIN and the control. In the present study, the allelic frequencies of rs11134527 were only significantly different in the comparison of CIN and cervical cancer groups with control group, but not in the comparison of CIN group with cervical cancer group.

###### The characteristics of five SNPs found in miRNAs and their related association studies with cancers

  miRNA locus     Function        SNPs         Alleles (case/control)                  Diseases/reference           Population(region)                   *P* value
  --------------- --------------- ------------ ------------------------ -------------- ---------------------------- ------------------------------------ --------------
  Pri-miR-218-2   Anti-oncogene   rs11134527   A                        G                                                                                
                                               1321/1538                897/1012       ESCC \[[@R26]\]              Han Chinese (Taizhou and Shanghai)   0.595
                                               346/599                  258/427        HCC \[[@R27]\]               Han Chinese (Sichuan)                0.670
                                               1928/1662                1202/1120      Cervical Cancer \[[@R28]\]   Han Chinese (Shanghai)               0.145
  Pri-miR-124-1   Anti-oncogene   rs531564     C                        G                                                                                
                                               1901/2151                317/399        ESCC \[[@R26]\]              Han Chinese (Taizhou and Shanghai)   0.191
                                               290/434                  26/86          Cervical Cancer \[[@R37]\]   Han Chinese (Zhengzhou)              0.001
                                               197/353                  17/63          Cervical Cancer \[[@R38]\]   Han Chinese (Guangdong)              0.014
  Pri-miR-145     Anti-oncogene   rs74693964   C                        T                                                                                
                                               no reference             no reference   no reference                 no reference                         no reference
  Pri-miR-133a2   Anti-oncogene   rs6062251    C                        T                                                                                
                                               no reference             no reference   no reference                 no reference                         no reference
  Pri-miR-100     Anti-oncogene   rs1834306    A                        G                                                                                
                                               217/189                  279/399        ESCC \[[@R50]\]              Kazakh Chinese (Xinjiang)            8.37×10^−5^
                                               92/377                   114/457        Cervical Cancer \[[@R51]\]   Han Chinese (Guangzhou)              0.892

Recent studies have reported that miR-124 suppresses a series of genes involved in the growth of human cancers. MiR-124 suppresses tumour growth through targeting STAT3 in colorectal cancer \[[@R29]\], CD151 in breast cancer \[[@R30]\], and ERK in cutaneous squamous cell carcinoma \[[@R31]\]. In cervical cancer, Wan *et al*. reported that miR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 \[[@R32]\], and Zhang *et al*. showed that miR-124 inhibits the proliferation, invasion, migration and epithelial-mesenchymal transition of cervical cancer \[[@R33]\]. As an anti-oncogene, significantly lower miR-124 expression was detected in cervical cancer than in low-grade squamous intraepithelial lesions \[[@R34]\]. Studies have shown that SNPs in miRNA genes might alter miRNA expression or function \[[@R35], [@R36]\]. Thus, SNPs in miR-124 might be associated with miR-124 expression and are further associated with cervical cancer. Rs531564 has been significantly correlated with the risk of various cancers (Table [7](#T7){ref-type="table"}), including cervical cancer and oesophageal squamous cell carcinoma (ESCC) \[[@R26], [@R37], [@R38]\]. In the present study, rs531564 in pri-miR-124-1 was associated with cervical cancer risk (*P*=0.017, OR=1.341; 95%CI: 1.054-1.706). Additionally, this SNP was correlated with the progression from CIN to cervical cancer (*P*=0.019; OR=1.385; 95%CI:1.054\~1.819). These results were consistent with the results of Wu *et al*., showing that the C allele is a risk factor for cervical cancer \[[@R37]\]. However, there was no significant association of rs531564 with CIN in the present study. It is likely that this polymorphism in pri-miR-124-1 is only associated with cervical cancer but not CIN. The two different stages (CIN and cervical cancer) of cervical cancer have different nosogenesis; thus, the same SNP may play different roles in two different disease stages.

MiR-145, a tumour suppressor, has been implicated in the death-promoting regulatory loop of P53 \[[@R39]\]. The downregulation of miR-145 has been associated with aggressive progression and poor prognosis in cervical cancer \[[@R40]\]. In 2015, Chacon-Cortes *et al* reported the association of rs353291 in miR-145 with breast cancer susceptibility \[[@R41]\]. However, in the present study, we investigated the association of rs74693964, another SNP in near Gene-3 of miR-145, with cervical cancer in a Chinese population; no significant association of rs74693964 with CIN and cervical cancer was detected.

MiR-133a plays a crucial role in myoblast proliferation and differentiation. Recent studies have shown the downregulation of miR-133a in human cancers. Accumulating evidence has indicated that the restoration of miR-133a expression could induce the suppression of cell proliferation, migration and invasion, and tumour cell apoptosis \[[@R42]--[@R44]\], indicating that miR-133a might act as a tumour suppressor in human cancers, including cervical cancer \[[@R45]\]. Zhou *et al* reported that rs8089787 and rs9948906 in miR-133a1 were associated with the risk of asthma in a Chinese Han population \[[@R46]\]. Paula *et al* analysed the association of rs13040413 and rs200375711 in miR-133a2 with long QT syndrome and observed no association between the two SNPs with long QT syndrome \[[@R47]\]. In the present study, we investigated the association of rs6062251 in the near Gene-3 of miR-133a2 with the initiation and development of cervical cancer. These results showed that the genotypic frequencies were significantly different between control, CIN and cervical cancer groups. The inheritance analysis showed that T/T-C/C genotype were correlated with increased risk of progression from CIN to cervical cancer in the overdominant model (*P*=0.007, OR=1.45; 95%CI: 1.11-1.90).

In recent years, miR-100 has been reported to target numerous biomolecules associated with carcinogenesis, suggesting that miR-100 functions as both a tumour promoter and a tumour suppressor. In cervical cancer, miR-100 functions as a potential tumour suppressive miRNA involved in tumour occurrence, development and drug resistance \[[@R48]\]. Li *et al*. \[[@R49]\] reported the reduced expression of miR-100 in CIN and cervical cancer. Zhu *et al*. reported that a SNP in miR-100 was associated with various types of diseases (Table [7](#T7){ref-type="table"}) \[[@R50]\]. In the present study, we did not observe any association of rs1834306 in pri-miR-100 with the initiation and development of cervical cancer in a Chinese Han population. Similarly, Xiong *et al*. detected no relationship between rs1834306 in pri-miR-100 and cervical cancer risk in a Chinese Han population (Table [7](#T7){ref-type="table"}) \[[@R51]\].

In current study, our results showed the allele or genotype of given miRNA played different roles in normal tissue, CIN and/or cervical cancer. The reason for the discrepancies could be the onset of cervical cancer is a multistep process that means progression of cervical cancer is from normal tissue to invasive cervical cancer through a series increasing grades of squamous intraepithelial lesions \[[@R52]\]. Among this multistep process, the miRNAs expression and their targets have shown discrepancies. For example, the expression of miR-145, miR-218 and miR-100 was progressive reduced and down-regulated from CIN 1 to 3 and cervical cancer versus normal tissue \[[@R53]--[@R55]\]. Furthermore, the miRNA expression alternation could change their targets function. In 2012, Qin *et al*. reported that miR-133b expression in CIN 2, 3 and cervical carcinoma had a gradual raise, which increased AKT and MAPKs (ERK1 and ERK2) phosphorylation augmenting tumorigenesis \[[@R56]\]. Their finding indicated miRNAs could play different roles in the progression of cervical cancer. Therefore, the different alleles or genotypes of SNPs in these miRNAs could function differently in the multistep stages of cervical cancer by altering their expression level and the binding affinity between them and their targets.

In summary, we investigated the association of the SNPs in five anti-oncogene miRNAs (pri-miR-218-2, pri-miR-145, pri-miR-133a2, pri-miR124-1 and pri-miR-100) with the CIN and cervical cancer in a Chinese Han population. The results showed that the A allele of rs11134527 in pri-miR-218-2 maybe associated with decreased risk of cervical cancer (OR=0.836; 95%CI: 0.708\~0.988) and may be a protective factor for the initiation of CIN (OR=0.786; 95%CI: 0.653\~0.946), and the C allele of rs531564 in pri-miR-124-1 may be associated with increased risk of cervical cancer (OR=1.341; 95%CI: 1.054-1.706) and maybe a risk factor for the progress form CIN to cervical cancer (OR=1.385; 95%CI: 1.054-1.819) in a Chinese Han population.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The present study was approved through the Institutional Review Board of the 3rd Affiliated Hospital of Kunming Medical University. The methods of this investigation were performed in accordance with the approved guidelines and principles expressed in the Helsinki Declaration of 1975, which was revised in 2008. All participants provided written informed consent.

Subjects {#s4_2}
--------

A total of 400 CIN and 609 cervical cancer patients were recruited at the 3rd Affiliated Hospital of Kunming Medical University from 2011 to 2015. The diagnosis of CIN and cervical cancer was confirmed by pathological examination according to "Diagnosis and Treatment Obstetrics and Gynaecology" and FIGO stage (International Federation of Gynaecology and Obstetrics, 2009). Subjects with oncotherapy history or other malignancy or incomplete clinical data were excluded from the present study. During the same period, 583 healthy women undergoing routine health check-ups at the same hospital were designated as the control group. The inclusion criteria of control subjects were HPV-negative women without any cervical lesions. All participants were self-reported as ethnically Han.

Genomic DNA extracted {#s4_3}
---------------------

Genomic DNA was extracted from peripheral lymphocytes using the QIAamp Blood Mini Kit (Qiagen, Hilden, German).

MicroRNA selection and sequencing {#s4_4}
---------------------------------

A total of nineteen miRNAs associated with cervical cancer \[[@R18]\] were sequenced (the sequencing ranged from 200bp upstream to 200bp downstream of miRNA genes) in 50 healthy individuals to search for SNPs (miR-124-1, miR-9-2, miR-100, miR-101-2, miR-214, miR-218-1, miR-218-2, miR-424, miR-7-1, miR-7-2, miR-7-3, miR-21, miR-23B, miR-31, miR-127, miR-133a2, miR-145, miR-205 and miR-3529).

SNP genotyping using TaqMan assay method {#s4_5}
----------------------------------------

SNPs, namely, rs11134527 in pri-miR-218-2, rs74693964 in pri-miR145, rs6062251 in pri-miR-133a2, rs531564 in pri-miR-124-1 and rs1834306 in pri-miR-100, were genotyped through PCR amplification using the TaqMan assay. The TaqMan assays including the primers and probes were designed and ordered by Applied Biosystems (<https://bioinfo.appliedbiosystems.com/genome-database/snp-genotyping.html>). Briefly, these SNPs were genotyped in 384-well plates using TaqMan assays in the QuantStudio 6 Flex Fast Real-Time PCR System. Amplification was performed in a 5-μl reaction volume consisting of 2.5 μl 2 × TaqMan Master Mix, 0.125 μl 40 × Primer and TaqMan Probe (FAM VIC) dye mix, 1.375 μl ddH~2~O, and 1 μl template DNA (substituted by equivalent ddH~2~O in negative control). The following PCR cycle conditions were used: 95°C for 10 min; PCR stage 92°C for 10 s and 60°C for 1 min repeated in 40 cycles. Data acquisitions and analysis were performed on QuantStudio™ real-time PCR software. To identify the accuracy of SNP genotyping using the TaqMan assay, three positive controls and one negative control were simultaneously genotyped using the TaqMan assay.

Statistical analysis {#s4_6}
--------------------

The allelic and genotypic frequencies of the SNPs were calculated using a direct-counting method. Hardy-Weinberg equilibrium (HWE) was tested for the SNPs in the control group. A *χ^2^* test was used to determine differences in allelic and genotypic frequencies, and the odds ratios (OR) with associated 95% confidence intervals (CIs) of allele and genotype-specific risks were calculated. The ages among different groups were compared using one-way ANOVA, followed by the LSD test for multiple comparisons correction. The association of each SNP with CIN and cervical cancer was analysed for the model of inheritance using SNPStats software \[[@R57]\]. The Akaike information criterion (AIC) and Bayesian information criterion (BIC) were used to determine the best-fit model for each SNP. The model with the smallest AIC and BIC values corresponds to minimal expected entropy. The statistical analyses were performed using SPSS 13 (Chicago, IL). A *P* value less than 0.05 was considered statistically significant.

We are grateful for participation of the patients and control subjects in this study. Appreciation is also owned to all physicians and nursing staff of the 3^rd^Affiliated Hospital of Kunming Medical University.
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